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Ethnopharmacological  relevance:  An  ethnopharmacological  survey  indicated  that  the  leaves  of  Byrsonima
intermedia  A. Juss.  (Malpighiaceae),  a medicinal  species  commonly  found  in the Brazilian  Cerrado,  can be
used against  gastroduodenal  disorders,  such  as  gastric  ulcers  and  diarrhea.
Aim of the  study:  The  objective  of  this  study  was  to evaluate  the  effects  of  a  methanolic  extract  of Byrsonima
intermedia  (MBI)  leaves  on gastric  and  duodenal  ulcers  and  to  assess  the  antimicrobial  and  antidiarrheal
effects  of this  extract.
Material and  methods:  The  anti-ulcerogenic  effect  of  MBI  was  investigated  with  different  ulcerogenic
agents  in  rodents  (mice  and  rats),  including  non-steroidal  anti-inﬂammatory  drug  (NSAID), HCl/ethanol,
pyloric  ligature,  absolute  ethanol,  cysteamine  and  ischemia–reperfusion.  The gastroprotective  effect  of
MBI was  assessed  by  analysing  the  volume  of  gastric  juice,  pH, total  acidity,  mucus,  NO,  sulfhydryl  com-
pound,  vanilloid  receptor,  glutathione  (GSH)  levels,  and myeloperoxidase  (MPO)  activity  in the  gastric
and  duodenal  mucosa.  The  gastric  and  duodenal  healing  effects  of MBI  were  also  evaluated  during  7 or
14  days  of treatment.  The  antidiarrheal  action  (measured  by  intestinal  motility  and  diarrhea  induced  by
castor oil)  and  anti-bacterial  action  of  MBI  against  Staphylococcus  aureus,  Escherichia  coli  and  Helicobacter
pylori  were  also  evaluated  by microdilution  methods.
Results:  The  phytochemical  proﬁle  from  MBI  indicated  the presence  of  phenolic  acids,  ﬂavan-3-ols,
oligomeric  proanthocyanidins,  and ﬂavonoids.  MBI  (500  mg/kg,  p.o.)  signiﬁcantly  inhibited  totally  gas-
tric  and  duodenal  lesions  (69%)  and  healed  gastric  (49%  on 14  days)  and  duodenal  lesions  (45% on 7 and
14 days).  The  MBI  exert  gastroprotective  action  by participation  of  endogenous  sulfhydryl  compounds,
vanilloid  receptors  and  increase  in  GSH  level  to effective  gastric  and  duodenal  protection.  MBI  also  dis-
played  curative  (42%)  and  preventive  (49%)  antidiarrheal  effects  by  involvement  of  opiate  receptors  and
also antimicrobial  effects  in  vitro.
Conclusions:  Byrsonima  intermedia  leaves  present  gastroprotective,  healing  and  antidiarrheal  activities,
supporting  previous  claims  that  its traditional  use  can  treat  gastrointestinal  disorders.. Introduction
Byrsonima intermedia A. Juss. (Malpighiaceae) is a keystone
pecies that plays a critical role in the maintenance of the Cerrado
iome structure (Vilas Boas, 2009). This species is popularly
alled “murici-pequeno” and is commonly found in the Cerrado
∗ Corresponding author. Tel.: +55 01438116077; fax: +55 1438153744.
E-mail address: hiruma@ibb.unesp.br (C.A. Hiruma-Lima).
378-8741 ©  2011 Elsevier Ireland Ltd. 
oi:10.1016/j.jep.2011.12.008
Open access under the Elsevier OA license.© 2011 Elsevier Ireland Ltd. 
of the city of Botucatu, São Paulo, Brazil. This medicinal species
is used in popular medicine in cases of fever, skin infection,
stomach ache, diarrhea and dysentery and as a diuretic and
anti-asthmatic (Sannomiya et al., 2007; Rinaldo et al., 2010).
Rodrigues & Carvalho (2001) have described the preparation of
this medicinal plant in an infusible form as astringent against
diarrhea or dysentery (3–4 cups/day). Rinaldo et al. (2010) have
Open access under the Elsevier OA license.evaluated the difference between the methanolic extract and
the infusible form from the leaves of Byrsonima intermedia and
have shown that the extract presents higher amounts of ﬂavan-
3-ols than the infusible form per gram of leaves. Previous
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nvestigations regarding the chemical composition of this
pecies have resulted in the isolation of quercetin-3-O--d-
alactopyranoside, (+)-catechin, (−)-epicatechin, gallic acid,
ethyl gallate, quercetin-3-O--l-arabinopiranoside and
mentoﬂavone (Sannomiya et al., 2007). Although some phyto-
hemical studies of this species exist, no pharmacological studies
ave been performed to assess the anti-ulcer or antidiarrheal
ction of this species as a folk medicine. Therefore, the aim of the
resent study was to evaluate the protective and healing effects of
ethanolic extract from the leaves of Byrsonima intermedia against
astric and duodenal ulcers and to evaluate the antidiarrheal effect
f this medicinal plant in a rodent experimental model.
. Materials and methods
.1. Drugs and chemicals
Analytical grades of the following chemicals were from
igma Chemical Co. (St. Louis, USA) and used in this study:
bsolute ethanol, hydrochloric acid, (Sinth, Brazil), lansopra-
ole and piroxicam (Hexal, Brazil), N-nitro-l-arginine methyl
ster (l-NAME), carbenoxolone, cimetidine, N-ethylmaleimide
NEM), Alcian Blue, cysteamine, castor oil, atropine, lop-
ramide, morphine, methanol, and dichloromethane. Gallic
cid, (+)-catechin, (−)-epicatechin, methyl gallate and tri-
uoroacetic acid (TFA) were also obtained from Sigma
hemical Co. (St. Louis, USA). 3,4-Di-O-galloylquinic acid,
,3,5-tri-O-galloylquinic acid, 1,3,4,5-tetra-O-galloylquinic acid,
uercetin-3-O--galactopyranoside, quercetin-3-(2′′-O-galloyl)-
--galactopyranoside, quercetin-3-O--arabinopyranoside and
uercetin-3-O-(2′′-O-galloyl)--arabinopyranoside were isolated
y the authors, and their structures were fully characterized by
V, MS, 1H-NMR and 13C-NMR data. The purity of each compound
as determined to be higher than 98%. HPLC-grade methanol
as obtained from Tedia (Phillipsburg, USA). HPLC-grade water
18 M cm)  was obtained using a Direct Q5 Milli-Q puriﬁcation
ystem (Millipore Co., Bedford, USA). Sep-Pak RP18 cartridges
500 mg/6 mL)  for solid phase extraction (SPE) were obtained from
aters Co. (Waters, Milford, USA). In the SPE step, the MBI  (10 mg)
as dissolved in 1 mL  of methanol and applied to a Sep-Pak
P18 cartridge that had been preconditioned with methanol
2 × 6 mL). The cartridge was eluted with methanol (6 mL)  to
emove chlorophyll, and the efﬂuent was collected and evaporated
nder a nitrogen stream. The solid obtained was re-dissolved in
ethanol/water (1:1, v/v), ﬁltered through a 0.45 m nylon ﬁlter
embrane (Sigma–Aldrich, St. Louis, USA), and aliquots (20 l)
ere submitted to HPLC analysis. All samples and reagents were
repared immediately before use.
.2. Plant material and extraction
Leaves of Byrsonima intermedia A Juss. were collected in July
007 from Pratânia city, São Paulo, Brazil. This species was identi-
ed by Prof. J. Tamashiro from the Institute of Biology, UNICAMP,
ampinas, SP, Brazil, and a voucher specimen (Ref. No. 24164) was
eposited at the IBB herbarium at the UNESP-Botucatu, SP, Brazil.
fter collection, the plant material was shade-dried, pulverized by
 mechanical grinder, passed through a 40 mesh sieve and stored
t room temperature until extraction. The dried powdered plant
aterial (0.59 kg) was extracted exhaustively with successions of
ethanol at room temperature (48 h). The extract was ﬁltered and
oncentrated under reduced pressure at 60 ◦C with a rotary evapo-
ator to generate the methanolic extract from Byrsonima intermedia,
hich was named MBI  (85.2 g). Upon low-pressure evaporation ofrmacology 140 (2012) 203– 212
the solvent from the extract, residues were obtained (14.5% (w/w)
with respect to dry powder material).
2.3. Chromatographic analyses of MBI
The MBI  TLC analyses, which were performed according to the
method of Wagner et al. (1984),  showed positivity for ﬂavonoids
and tannins. The crude extract (10.0 g) was  then suspended in
H2O and partitioned with EtOAc. The concentrated EtOAc frac-
tion (4.0 g) was chromatographed on a gel permeation column
(GPC, Sephadex LH-20, Pharmacia) (57 cm × 3 cm H × i.d.), eluted
with MeOH, and yielded 195 fractions (15 mL). The fractions were
analyzed by Thin Layer Chromatography (TLC) on silica gel plates
eluted with a mixture of CHCl3/MeOH/H2O (80:18:2, v/v/v) and
revealed either with NP/PEG reagent or with anisaldehyde/sulfuric
acid solution (Wagner et al., 1984). Fractions showing similar TLC
data were grouped, furnishing 17 major fractions. Fractions 48–52
(319.0 mg)  were separated over a successive silica gel column
(Merck), and its compounds were eluted with CHCl3/MeOH (75:25,
v/v) furnishing quercetin-3-O--d-galactopyranoside 1 (7.0 mg), a
mixture of (+)-catechin 2 and (−)-epicatechin 3 (11.0 mg). Frac-
tions 39–42 (74.0 mg)  were processed by semi-preparative HPLC
using a Phenomenex Luna RP18 (2) column (250 mm × 10 mm;
H × i.d., 10 m,  ﬂow rate: 2.0 mL/min). The mobile phase used was
MeOH/H2O (7:3) and furnished the following pure compounds:
gallic acid 4 (6.0 mg), methyl gallate 5 (7.2 mg)  and quercetin-3-O-
-l-arabinopiranoside 6 (7.0 mg). The biﬂavonoid amentoﬂavone
7 (9.0 mg)  was  obtained from fractions 77–94 (222 mg)  by succes-
sive chromatographic columns on silica gel (Merck) eluted with
CHCl3/MeOH (90:10, v/v). The elucidation of the structure of the
isolated compounds was  determined using spectral data, such as
1H, 13C, HSQC, HMQC, COSY and NOESY-NMR spectra elucidation
and EI-MS spectra evaluation. The NMR  spectra were obtained on
a Varian Inova 500 MHz.
2.4. Chromatographic proﬁling and identiﬁcation of MBI
The chemical composition of MBI  was investigated by High Per-
formance Liquid Chromatography coupled to a Photodiode Array
Detector (HPLC-PAD), using a Jasco (Tokyo, Japan) HPLC equipped
with a PU-2089 quaternary solvent pump, a MD-2010 PAD and
an AS-2055 autosampler. The analytical column maintained at
room temperature (25 ◦C), was  a Phenomenex Synergi Hydro RP18
(250 mm × 4.6 mm H × i.d.; 4 m)  with a Phenomenex security
guard column (4.0 mm × 2.0 mm H × i.d.). Separation of phenolic
acids, ﬂavonoids, ﬂavan-3-ols and proanthocyanidins was estab-
lished using the mobile phase of water (eluent A) and methanol
(eluent B), both containing 0.1% triﬂuoroacetic acid (TFA), with
the following gradient program: 0–20% B (20 min), 20% B iso-
cratic (2 min), 20–50% B (38 min), 50–100% B (5 min), 100% B
isocratic (5 min), return to 0% B (2 min), and the column was  re-
equilibrated with the initial conditions for 18 min  before the next
injection. The ﬂow rate was 1.0 mL/min, and the total run time was
90 min. EZChrom Elite Data System software (Chromatec, Idstein,
Germany) was  used for both detector operation and data pro-
cessing. The identiﬁcation of the compounds was performed by
retention time comparison, UV spectral analyses and by spiking
with commercial or isolated standards under the same conditions.
2.5. Animals
Male Swiss albino mice (25–35 g) and male Wistar albino rats
(150–250 g) from the Central Animal House of the UNESP were
used. The animals were fed a certiﬁed Nuvilab® (Nuvital) diet
with free access to tap water under standard conditions of 12 h
dark–12 h light, humidity (60 ± 1.0%) and temperature (21 ± 1 ◦C).
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he animals were fasted prior to all assays because standard
rugs and MBI  were always administered orally (gavage) using a
aline solution (0.9% NaCl, 10 mL/kg) as the vehicle. The animals
ere housed in cages with raised ﬂoors of wide mesh to prevent
oprophagy. All experiments were performed in the morning and
ollowed the recommendations of the Canadian Council on Animal
are (Olfert et al., 1993). The UNESP Institutional Animal Care and
se Committee approved all of the employed protocols (CEUA no.
8/05).
.6. Evaluation of gastroprotective activity
Ethanol-induced ulcer – This experiment was performed as
escribed by Morimoto et al. (1991).  Male rats were distributed
nto 5 groups (n = 8) and fasted for 24 h prior to receiving an oral
ose of the vehicle (10 mL/kg), lansoprazole (30 mg/kg) or MBI  (250,
00 or 1000 mg/kg body weight). After 60 min, all groups were
reated orally with 1 mL  of absolute ethanol to induce gastric ulcers.
fter another 1 h, the animals were sacriﬁced, and the extent of the
esions was measured by AvSoft® Bioview Spectra, Brazil; the lesion
easurements are expressed as mm2.
NSAID-induced gastric ulcers in mice – In this model (Puscas et al.,
996), gastric lesions were induced with piroxicam (30 mg/kg, s.c.)
dministered to male Swiss mice (n = 8) after a 24 h fast. MBI  (250,
00 or 1000 mg/kg body weight), cimetidine (100 mg/kg) or vehicle
as orally administered 30 min  before the induction of the gastric
esions. The animals were sacriﬁced 4 h after treatment with the
lcerogenic agent. The stomachs were removed, and gastric lesions
ere measured as described above.
HCl/ethanol-induced ulcer – The experiments were performed
s described by Mizui and Doteuchi (1983),  with modiﬁcations.
ale Swiss mice (n = 5) were distributed into groups of 5 ani-
als that were fasted for 24 h prior to receiving an oral dose
f the vehicle (10 mL/kg), lansoprazole (30 mg/kg) or MBI  (250,
00 or 1000 mg/kg body weight). After 50 min, all groups were
rally treated with 0.2 mL  of a 0.3 M HCl/60% ethanol solution
HCl/ethanol) for gastric ulcer induction. The animals were sacri-
ced 1 h after the administration of HCl/ethanol, and the gastric
amage was measured as described above.
Shay ulcer – All male mice (n = 8–9) were randomly divided into
hree groups and fasted for 18 h with free access to water. Thirty
inutes after oral administration of MBI  (500 mg/kg, which is the
owest dose that presents signiﬁcant results in all acute exper-
ments), cimetidine (100 mg/kg) as a positive control or vehicle
10 mL/kg), pylorus ligature was performed as described by Shay
1945).  Four hours later, the animals were sacriﬁced, the abdomen
as opened, and another ligature was placed around the oesopha-
us close to the diaphragm. The stomach was removed and lesion
as measured (mm2), and the gastric juice volume (mL), hydrogen
on concentration (mEq/mL/4 h) and pH (unit) were recorded.
Determination of gastric secretion – The assay was performed
ccording to the method of Shay (1945) with a few modiﬁca-
ions. All groups of male mice (n = 9–10) were fasted for 18 h
ith free access to water. Immediately after pylorus ligature, MBI
500 mg/kg), cimetidine (100 mg/kg) as positive control or vehi-
le (10 mL/kg) was administered by an intraduodenal route. The
nimals were sacriﬁced 4 h later, the abdomen was  opened, and
nother ligature was placed around the oesophagus close to the
iaphragm. The stomachs were removed, the gastric lesions were
easured (mm2) and the gastric content was collected to deter-
ine the total amount of gastric juice acid (mL) and pH valuesunit). Distilled water was added, and the resultant solution was
entrifuged at 3000 × g for 10 min. Total acid in the gastric secre-
ion volume was determined in the supernatant by titration to pH
.0 with 0.01 N NaOH (mEq/mL/4 h).rmacology 140 (2012) 203– 212 205
Assessment of mucus adhered to the gastric wall – The procedure
was performed according to the methods of Rafatullah et al. (1990).
After fasting for 18 h, a longitudinal incision was made below the
xiphoid apophysis for the pylorus ligature in anaesthetized rats
(n = 6–7). Vehicle (10 mL/kg), carbenoxolone (200 mg/kg) or MBI
(500 mg/kg) was administered (p.o.) for 1 h before the ligature. Four
hours later, the animals were sacriﬁced, and the glandular portion
of the stomach was separated, weighed and immersed in a solu-
tion of Alcian Blue to quantify the mucus. For each sample, the
absorbance at 598 nm was measured in a spectrophotometer, and
the results are expressed as g of Alcian blue/g of tissue.
Ethanol-induced gastric lesions in l-NAME-, NEM-, and Ruthenium
Red-pretreated rats – The procedure was  performed according to the
methods of Pongpiriyadacha et al. (2003),  Matsuda et al. (1999) and
Morimoto et al. (1991).
Gastric mucosal lesions were induced in male Wistar rats. To
investigate the involvement of SHs in the protective effect of
MBI  (500 mg/kg), NEM (an SH-blocker, 10 mg/kg) or vehicle was
injected 30 min  before the administration of MBI. To investigate
the possible involvement of endogenous NO in the protective effect
of MBI, l-NAME (an inhibitor of NOS, 70 mg/kg) or vehicle was
administered 30 min  before the administration of MBI. To inves-
tigate the possible involvement of the vanilloid receptor in the
protective effect of MBI, Ruthenium Red (RR, 6 mg/kg), which has
been reported to be an antagonist against capsaicin, or vehicle was
injected 30 min  before the administration of MBI. After 60 min, all
groups were orally treated with 1 mL  of absolute ethanol for gas-
tric ulcer induction. The animals were sacriﬁced 1 h after ethanol
administration, the stomachs were excised, and the gastric lesions
were measured as described above.
Determination of total glutathione (GSH) in gastric mucosa in NEM-
pretreated rats and RR-pretreated rats – The GSH present in the
samples was  quantiﬁed by the method described by Anderson
(1985).  Stomachs obtained from the investigation of the role of
sulfhydryl compounds and the involvement of the vanilloid recep-
tor in the gastric protection experiment were cut into slices and
placed in an Eppendorf containing 5% TCA at a 1:20 (w/v) pro-
portion. The samples were homogenized in 5% TCA using a Potter
cell macerator (Marconi®, Brazil). After two  centrifugation steps
(2000 × g and 9000 × g for 5 and 10 min, respectively) at 4 ◦C, the
supernatants were removed to quantify the glutathione through
reaction with DTNB (5,5′-dithiobis(2-nitrobenzoic acid). The results
were obtained as nmol/g of wet  tissue.
Acute gastric mucosal lesions induced by ischemia–reperfusion in
rats – Ischemia–reperfusion (I/R) erosions were produced in three
groups of rats (n = 8–10) by the method originally proposed by Ueda
et al. (1989).  The rats were deprived of food but allowed access to
tap water ad libitum for 18 h before the experiments. Brieﬂy, under
anaesthesia (0.8 mg/kg of ketamine hydrochloride and 0.4 mg/kg
xilazine hydrochloride), the celiac artery was clamped with a small
clamp for 30 min. Then the clamp was removed, and reperfusion
occurred for 60 min. Vehicle (10 mL/kg), lansoprazole (30 mg/kg)
or MBI  (500 mg/kg) was administered orally 60 min  prior to the
experiments. The untreated group comprised animals that were
submitted to the abdominal incision, but not to I/R. After 60 min
of reperfusion, the animals were sacriﬁced, and their stomachs
were excised. The gastric mucosal injury was measured by AvSoft®
Bioview Spectra, Brazil and expressed as mm2. Then the gastric
mucosa was stored at −80 ◦C for biochemical measurements of GSH
levels and MPO  activity.
Biochemical determinations from gastric mucosa after gastric
ischemia–reperfusion (I/R) injury – The MPO  level was  measured
according to the technique described by Krawisz et al. (1984). Sam-
ples were suspended in 1 mL  of 50 mM phosphate buffer with 0.5%
hexadecyltrimethylammonium bromide (pH 6.0) and minced with
scissors for 15 s on an ice-cold plate. The resultant suspension was
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ubsequently diluted to a ﬁnal 1:20 (w/v) ratio and homogenized
or 1 min  with an automatic Heidolph homogenizer, sonicated for
0 s and subjected to three freeze–thaw cycles. The homogenates
ere then centrifuged at 7000 × g at 4 ◦C for 10 min, and the super-
atants were assayed for MPO  activity. The results are expressed as
PO  units per gram (U/g) of wet tissue. The measurement of GSH
ontent has already been described.
.7. Evaluation of healing of gastric ulcers induced by acetic acid
n rats
The experiments were performed according to the method
escribed by Okabe et al. (1971) modiﬁed by Konturek et al. (1988).
ix groups of male Wistar rats that were fasted for 18 h were used
n this experiment (n = 8). Under anaesthesia, a laparotomy was
erformed on all animals through a midline epigastric incision.
fter exposing the stomach, 0.05 mL  (v/v) of 80% acetic acid solu-
ion was injected into the subserosal layer in the glandular part of
he anterior wall. The stomach was bathed with saline (20 ◦C) to
void adherence to the external surface of the ulcerated region.
he abdomen was then closed, and all of the animals were fed
ormally. All treatments, including MBI  (500 mg/kg body weight),
ansoprazole (30 mg/kg) or vehicle (10 mL/kg), were administered
rally once a day for 7 or 14 consecutive days beginning one day
fter surgery. On the day after the last drug administration, the
ats were sacriﬁced and their stomachs were removed. The gas-
ric lesions were evaluated by examining the inner gastric surface
ith a dissecting magnifying glass. The macroscopic ulcer area was
ecorded using AvSoft® Bioview Spectra, Brazil and expressed as
m2.
.8. Evaluation of the preventive effect of MBI  on duodenal ulcers
n rats
Cysteamine duodenal ulcer in rats and determination of GSH and
PO  activities – Male Wistar albino rats, weighing 150–250 g were
sed, and food and water were available ad libitum throughout the
ssay. Duodenal ulcers were induced by two oral administrations
f cysteamine hydrochloride (400 mg/kg) in saline solution at an
nterval of 4 h. MBI  (500 mg/kg), lansoprazole (30 mg/kg), or vehi-
le (10 mL/kg) were administered 30 min  before the ﬁrst dose of
ysteamine. One untreated group was used to evaluate the nor-
al  parameters of the duodenum mucosa. All of the animals were
acriﬁced 48 h after the ﬁrst dose of cysteamine. Each duodenum
as cut open along the antimeseteric side and rinsed with saline.
he duodenal score was determined using the following 4-point
cale: 0 = no lesion; 1 = superﬁcial mucosal erosion; 2 = deep ulcer
r transmural ulcer; and 3 = perforated or penetrated ulcer (Szabo,
978).
.9. Evaluation of the healing of duodenal ulcers induced by
cetic acid in rats
The experiments were performed according to the method
escribed by Okabe et al. (1971) modiﬁed by Konturek et al. (1988).
ix groups of male Wistar rats (200–250 g) were deprived of food
or 18 h, but had free access to water. An incision was  made in
he abdomen of animals under anaesthesia, and a plastic mould
4.2 mm in diameter) was placed tightly on the serosal surface
f the duodenal wall, approximately 5 mm distal to the pylorus.
cetic acid (80%, 70 l) was poured into the mould and allowed to
emain for 10 s. After removal of all acetic acid, the abdomen was
losed, and the animals were fed normally. All treatments were
dministered orally once a day for 7 or 14 consecutive days begin-
ing one day after surgery. To assess the duodenal healing effects,
he selected dose of MBI  (500 mg/kg body weight), lansoprazolermacology 140 (2012) 203– 212
(30 mg/kg) or vehicle (10 mL/kg) was  administered once a day to 3
groups for 7 days and to another 3 groups for 14 days. On the day
after the last drug administration, the rats were sacriﬁced, and their
duodena were removed. The duodenal lesions were evaluated by
examining the inner duodenal surface with a dissecting magnify-
ing glass. The macroscopic duodenal ulcer area was recorded and
expressed as mm2.
2.10. Antidiarrheal activity
Gastrointestinal motility (charcoal meal) in mice – Male Swiss
mice (n = 7) were weighed and deprived of food for 6 h, but had
free access to water. At time zero, the animals received vehicle
(saline) as the negative control, 5 mg/kg of atropine as the positive
control, or MBI  at doses of 250, 500 or 1000 mg/kg by oral gavage.
Thirty min  after the treatments, all groups received 10 activated
charcoal ((01, mL/10 g), orally) and were sacriﬁced 30 min later.
The results were expressed as percentage of the total length of the
small intestine. The distance travelled by the charcoal relative to the
total length of the small intestine was calculated for each mouse
to express the percentage of distance travelled and converted by
arcosine (Stickney and Northup, 1959, with modiﬁcations).
Intestinal ﬂuid accumulation – Following the method of Robert
et al. (1976),  male Swiss mice were divided into six groups of
seven or eight animals per group and half of them were pretreated
with saline and another one with naloxone – opioid antago-
nist (30 mg/kg, i.p.). Fifteen minutes later, groups were treated
with vehicle (10 mL/kg, p.o.), morphine (10 mg/kg, i.p.), or MBI
(500 mg/kg, p.o.) and one hour later, the mice received castor oil
(2 mL/animal) orally. The animals were sacriﬁced 1 h later, and the
small intestines were removed after ligation at the pyloric end and
ileocaecal junction and weighed. The contents of the intestine were
then expelled into a graduated tube, and the volume was measured.
The intestines were re-weighed, and the differences between the
full and empty intestines were calculated.
Diarrhea induced by castor oil: evaluation of preventive effect
of MBI – Three groups of male Swiss mice (n = 7) were orally
treated with vehicle (10 mL/kg), MBI  (500 mg/kg body weight)
or loperamide (5 mg/kg) 30 min  before castor oil (0.2 mL/animal)
administration. Immediately after ingesting castor oil, each animal
was kept in an individual cage, whose ﬂoor was lined with blotting
paper, and observed for 5 h. The following parameters were moni-
tored: time to initial evacuation (min), evacuation classiﬁcation – 1
(normal stool), 2 (semi-solid stool), and 3 (watery stool) and evac-
uation index (EI), expressed according to the formula: EI = 1 × (no
stool 1) + 2 × (no stool 2) + 3 × (no stool 3) (Awounters, 1978, mod-
iﬁed by Mukherjee et al., 1998).
Diarrhea induced by castor oil: evaluation of curative effect of MBI  –
Three groups of male Swiss mice (n = 8–9) were orally treated with
0.2 mL/animal with castor oil (p.o.). Then 15 min after administra-
tion of the cathartic agent, the groups were treated with vehicle
(10 mL/kg), MBI  (500 mg/kg body weight) or loperamide (5 mg/kg).
Immediately after ingesting the different treatments, each animal
was kept in an individual cage whose ﬂoor was lined with blot-
ting paper and observed for 4 h. The same parameters as described
above for the preventive evaluation (Awounters, 1978; Mukherjee
et al., 1998) were monitored.
2.11. Antibacterial susceptibility test
The antibacterial properties of MBI  were also tested. The bac-
terial strains (Escherichia coli ATCC 25922, Staphylococcus aureus
ATCC 25923, and Helicobacter pylori ATCC 43504) were tested using
a microdilution methods followed by CLSI (2006a, b),  and mini-
mal  inhibitory concentration (MIC) values were determined. E. coli
and S. aureus strains were inoculated on Mueller–Hinton agar
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Fig. 1. Analytical HPLC-PAD chromatogram recorded at 275 nm of the
compounds identiﬁed on the MBI. Peak identiﬁcation: (1) gallic acid, (2) 3,4-
di-O-galloylquinic acid, (3) methyl gallate, (4) catechin, (5) epicatechin, (6)
1,3,5-tri-O-galloylquinic acid, (7) 1,3,4,5-tetra-O-galloylquinic acid, (8) quercetin-
3-O--galactopyranoside, (9) quercetin-3-(2′′-O-galloyl)-O--galactopyranoside,
T
E
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lates and incubated at 37 ◦C for 24 h, and H. pylori was  inocu-
ated on Mueller–Hinton agar plates containing 5% sheep blood and
ncubated at 36 ◦C for 3 days in a 10% CO2 atmosphere. Inoculates
ere prepared in the same medium at a density adjusted to a 0.5
cFarland turbidity standard [108 colony-forming units (CFU)/mL]
or E. coli and S. aureus and 2.0 McFarland turbidity standard for H.
ylori. The working suspension for each microorganism was  diluted
:10, and a 100 l volume was added to each well of a microplate.
 100 l volume of Mueller–Hinton broth or the same volume of
ueller–Hinton broth supplemented with 10% foetal bovine serum
as added to each well of the microplates of E. coli and S. aureus,  and
. pylori,  respectively. The concentrations for each extract, prepared
n 2% DMSO, ranging from 0.5 to 1.000 g/L were obtained when
 100 l volume of the extract was transferred to the ﬁrst well of
ach row, and serial 2-fold dilutions were performed. Amoxicillin,
etronidazole, and tetracycline were used as reference antimicro-
ial compounds. The MICs were recorded after incubation of the
icroplates at 37 ◦C for 24 h (E. coli and S. aureus)  or 36 ◦C for 3
ays in a 10% CO2 atmosphere (H. pylori), and the growth was visu-
lly examined. The absorbance was determined using an automatic
icroplate reader adjusted to 600 nm.  The lowest concentration of
he test extract that ultimately caused an inhibition of bacterial
rowth of more than 90% was taken as the MIC.
.12. Statistical analysis
The results are expressed as the mean ± S.E.M. Statistical signif-
cance was determined by one-way analysis of variance followed
y Dunnett’s test, or no parametric results was determined by
ruskal–Wallis followed by Dunn’s test; levels of P < 0.05 were con-
idered to be statistically signiﬁcant.
. Results and discussion
The HPLC-PAD phytochemical characterization showed that
BI  presented several peaks that eluted in the retention
ime (Rt) range of 5–65 min  (Fig. 1). The metabolite classes
ere identiﬁed with PAD scanning from 200 to 600 nm.  In
he chromatogram in Fig. 1, the constituents of MBI  can be
ivided into the following three main classes: (I) phenolic
cids and catechin derivatives, (II) oligomeric proanthocyani-
ins and (III) ﬂavonoids. Based on this information and after
o-injection experiments, eleven peaks were unambiguously iden-
iﬁed as being associated with gallic acid (1, Rt = 15.1 min),
,4-di-O-galloylquinic acid (2, Rt = 23.9 min), methyl gallate
3, Rt = 28.6 min), (+)-catechin (4, Rt = 29.9 min), (−)-epicatechin
able 1
ffects of different doses from methanolic extract of Byrsonima intermedia (MBI) on mode
Methods (animal) Treatments (p.o.) Dose (mg/kg)
Absolute ethanol (rats) Vehicle – 
Lansoprazole 30 
MBI 250 
500 
1000 
NSAID (mice) Vehicle – 
Cimetidine 100 
MBI 250 
500 
1000 
HCl/ethanol (mice) Vehicle – 
Lansoprazole 30 
MBI 250 
500 
1000
esults are mean ± S.E.M. ANOVA followed by Dunnett’s test: gastric lesion. **P < 0.01.(10) quercetin-3-O--arabinopyranoside and (11) quercetin-3-O-(2′′-O-galloyl)--
arabinopyranoside. For chromatographic conditions see the Materials and Methods
section.
(5, Rt = 38.1 min), 1,3,5-tri-O-galloylquinic acid (6, Rt = 39.5),
1,3,4,5-tetra-O-galloylquinic acid (7, Rt = 41.7 min), quercetin-
3-O--d-galactopyranoside (8, Rt = 56.8 min), quercetin-3-(2′′-O-
galloyl)-O--d-galactopyranoside (9, Rt = 57.9 min), quercetin-3-
O--l-arabinopyranoside (10, Rt = 59.4 min) and quercetin-3-O-
(2′′-O-galloyl)--l-arabinopyranoside (11, Rt = 61.2 min). In addi-
tion to the monomeric ﬂavan-3-ols found in MBI, oligomeric
proanthocyanidins were suggested as the broad unresolved peak
that eluted in the Rt range of 35–60 min. This result is in accor-
dance with those obtained by Rinaldo et al. (2010),  who  compared
the methanolic extract and infusible form from the leaves of Byr-
sonima intermedia.  The extraction with methanol instead of water
did not show any selectivity in the extraction process; however,
the concentration of (+)-catechin and (−)-epicathechin was lower
in the infusible form.
As a part of the pharmacological study of the gastroprotective
effects of MBI, the extract was  evaluated in experimental models of
gastric ulcers induced by multiple damaging agents (Table 1). Gas-
tric mucosal injury frequently occurs when noxious factors, such
as NSAID, increased acid secretion, the presence of the bacteria
Helicobacter pylori,  ingestion of alcohol or mucosal ischemia over-
whelm the mucosal defence factors (Laine et al., 2008). Among the
three different doses of MBI  examined in this study, the gastropro-
tective effect was  found to be greatest at the dose of 500 mg/kg in
all experimental models. The gastric damage in the group treated
ls of gastric lesions induced in rodents.
N Gastric lesion (mm2) Inhibition (%)
8 150.5 ± 17.1 –
8 65.6 ± 16.7** 56
8 68.4 ± 13.9** 55
8 4.2 ± 1.8** 97
8 0** 100
8 27.2 ± 4.3 –
8 11.8 ± 2.6** 57
8 21.3 ± 3.6 –
8 12.4 ± 1.5** 54
8 9.8 ± 2.6** 64
5 91.4 ± 7.7 –
5 34.8 ± 6.6** 62
5 61.4 ± 3.2** 33
5 45.4 ± 6.6** 50
5 20.6 ± 3.4** 78
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Table 2
Effects of cimetidine and methanolic extract of Byrsonima intermedia (MBI) administered orally or intraduodenally on gastric juice parameters in pylorus ligature-induced
gastric lesions in mice.
Treatments Route Dose (mg/kg) N Gastric lesion (mm2) Inhibition (%) pH (unit) Volume (mL) [H+] (mEq/mL/4 h)
Vehicle p.o. – 8 16.7 ± 2.5 – 3.5 ± 0.3 0.9 ± 0.1 10.3 ± 1.0
Cimetidine 100 8 12.0 ± 1.7* 28 5.3 ± 0.5** 1.0 ± 0.1 6.2 ± 1.0*
MBI  500 9 7.5 ± 1.1** 55 3.3 ± 0.3 1.5 ± 0.2* 7.3 ± 1.2
Vehicle i.d. –  10 19.1 ± 2.8 – 3.0 ± 0.3 1.1 ± 0.1 10.2 ± 0.7
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MBI 500 9 6.6 ± 1.3**
esults are mean ± S.E.M. ANOVA followed by Dunnett’s test: *P < 0.05, **P < 0.01
ith MBI  was signiﬁcantly reduced by 50% (HCl/ethanol model),
4% (NSAID model) and 97% (absolute ethanol model) relative
o the control groups treated with vehicle. The lower dose of
BI  (250 mg/kg) did not exert a complete gastroprotective action
gainst NSAIDs, and a statistically signiﬁcant difference existed
etween the dose of 250 and 500 mg/kg (P < 0.05).
The next step of this study was the evaluation the effect
f MBI  on gastric juice parameters to evaluate the possible
nti-secretory action of the extract. The administration of this
xtract showed (Table 2) that oral treatment with MBI  decreased
he gastric lesion (55%) and increased the gastric volume (67%)
ithout changing the pH or H+ concentration relative to the control
roup treated with vehicle. The systemic effect of gastroprotec-
ion by MBI  was also observed by administration of this extract
hrough an intraduodenal route that induced the same alterations
n the gastric mucosa and gastric juice. Both results in Table 2
xcluded a possible anti-secretory action of MBI, like cimetidine,
nd showed that MBI  did not present a coating effect on gastric
ucosa. Therefore, the gastroprotective activity of MBI  could be
elated to a strengthening of the defence mechanisms of gastric
ucosa, such as mucus (Laine et al., 2008). The copious quanti-
ies of mucus from the gastric mucosa are the ﬁrst line of mucosal
efence against noxious agents in the lumen (Abdel-Salam et al.,
001). The effect of MBI  on increasing the gastric mucus produc-
ion was evaluated in pylorus ligature rats. In the group treated
nly with carbenoxolone (positive control), the amount of mucus
dhered to the gastric mucosa (12.4 ± 1.2 g/g of tissue) in rats
ncreased signiﬁcantly (P < 0.05) in relation to control group. The
roup treated with MBI  maintained the gastric mucus amount at
he same level as the control group treated with vehicle (8.6 ± 1.2
nd 8.5 ± 0.7 g/g of tissue, respectively). This result also discards
he effect of MBI  in increasing the amount of mucus as a gastro-
rotective defence mechanism. In addition to mucus, other defence
echanisms were also investigated, such as endogenous NO (nitric
xide), NP-sulfhydryl compounds and the TRPV1 receptor (tran-
ient receptor potential vanilloid type 1), which are important
actors that maintain mucosal integrity (Szabo and Nagy, 1992;
olzer, 2006).
Mucosal blood ﬂow is essential for the delivery of oxygen and
utrients, removal of toxic substances and normally blood ﬂow in
he gastric mucosa is increases in response to acid secretion (Abdel-
alam et al., 2001). Gastric blood ﬂow is mediated in part by NO,
owever sensory nerves are also involved in the regulation of gas-
ric blood ﬂow (Pawlik et al., 1998; Mártin et al., 2001; Jaworek
t al., 2002). The gastric mucosa is densely innervated by capsaicin-
ensitive afferent neurons containing vasodilator peptides, such as
he related peptide calcitonin gene (CGRP) (Sternini et al., 1987).
apsaicin affects these nerves by two different ways; a low-doses
timulation of sensory nerves, accompanied by the release of CGRP,
hile high doses of capsaicin lead to ablation or functional inac-ivation of sensory nerves (Warzecha et al., 2000). The release of
GRP by capsaicin-sensitive nerves have also been involved in the
aintenance of mucosal integrity because the ablation of func-
ional neurons results a decrease in reactivity to CGRP in the mucosa60 4.9 ± 0.5* 0.8 ± 0.1 6.1 ± 1.3*
66 3.7 ± 0.5 1.5 ± 0.1* 8.8 ± 1.0
and leads to a worsening of gastric lesions induced by various
ulcerogenic compounds (Brzozowski et al., 1996; Kwiecien´ et al.,
2002). For example, ethanol provides not only harmful effect by
decreasing the barrier function of mucus, but also activates TRPV1
receptors in sensory neurons of the gastric mucosa by stimulating
the release of substance P in the stomach, which in turn activates
NK1 receptors of gastric epithelial cells promoting the increase of
ROS (oxidative stress), that cause hemorrhagic lesions in the stom-
ach wall due to lipid peroxidation (Gazzieri et al., 2007).
Our results showed that pretreatment of animals with l-NAME
(a NO-synthase inhibitor) did not change the gastroprotective effect
of MBI  (P > 0.05) compared to the saline-pretreatment MBI  group
(inhibition 98% vs. 99%). Therefore, our results also exclude an
involvement of endogenous NO in the gastroprotective effect of
MBI  (data not shown). However, the group of animals that was
pretreated with Ruthenium Red (which blocks the TRPV receptor)
and treated with extract displayed a signiﬁcant increase in gastric
lesions by approximately 10-fold (37.7 ± 12.5 mm2) compared to
the group treated with MBI  (3.1 ± 2.9 mm2). The protective effect
of MBI  was also eliminated when the group was treated with a
sulfhydryl inhibitor (NEM) (P < 0.001). Both of these results, which
are shown in Table 3, suggest that the activity of MBI may involve
the TRPV receptor and the presence of SH compounds in the gas-
tric mucosa. This gastroprotective effect of MBI  demonstrated in
Table 3 was  also evidenced by a signiﬁcant increase in the levels
of total glutathione (GSH). GSH acts as an important antioxidant in
the gastric mucosa, and its presence is important for the mainte-
nance of mucosal integrity (Szabo and Nagy, 1992). The levels of
GSH in the gastric mucosa tend to decrease after administration of
absolute ethanol, but our results showed that pretreatment with
MBI  was able to inhibit this decrease in GSH (P < 0.05).
Ischemia also has deleterious effects on gastric mucosa and is
one of the stress-inducing gastric mucosal injuries (Laine et al.,
2008). The restoration of blood ﬂow (reperfusion) after a period
of ischemia initiates a cascade of changes, including the release of
local of reactive oxygen species (ROS) and an increase in the adhe-
sion of neutrophils to endothelial cells, which causes damage to
the integrity of the mucosal lining; this phenomenon is known as
ischemia–reperfusion (I/R) (Abdallah et al., 2009).
The gastric ulcerogenic response to I/R has been reported to
be signiﬁcantly mitigated by antioxidants systems (Harada et al.,
2001). Our results (Fig. 2) show that gastric injury signiﬁcantly
increased after 60 min  of reperfusion following 30 min  of ischemia
by clamping the celiac artery of rats. Our results show that MBI
markedly protected against gastric ulceration induced by I/R (88%).
This effect of MBI  was  not mediated by GSH because the level of
GSH decreased relative to the untreated group. Kobata et al. (2007)
have described a marked increase in mucosal MPO  activity in the
stomach after I/R, conﬁrming the inﬁltration/activation of neu-
trophils in the gastric mucosa during I/R. However, our results show
a signiﬁcant decrease in MPO  (P < 0.01), which breaks the vicious
cycle that exists between the formation of ROS and the inﬁltration
of inﬂammatory cells during I/R. Our results are consistent with
those obtained by Orlandi et al. (2011) that also characterized the
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Table 3
Effect of methanolic extract of Byrsonima intermedia (MBI) on gastric lesions and total glutathione level (GSH) in rats (n = 7–8) pretreated with NEM (SH blocker) or Ruthenium
Red  (RR – TRPV blocker) and treated with absolute ethanol.
Pretreatment (i.p.) Treatment (p.o.) Dose (mg/kg) Ulcerative lesion (mm2) Gastric lesion Inhibition (%) GSH (nmol/g)
Untreated 1070.2 ± 92.3
Saline+ Vehicle – 212.8 ± 49.8 – 607.7 ± 46.7&
Saline+ Carbenoxolone 100 0.1 ± 0.1** 100 895.2 ± 48.0**
Saline+ MBI  500 4.35 ± 4.4** 98 768.1 ± 27.8*
NEM+ Vehicle – 360.3 ± 91.9# – 411.2 ± 40.1&
NEM+ Carbenoxolone 100 240.2 ± 101.4*,# 33 661.6 ± 73.2&
NEM+ MBI 500 147.3 ± 42.2**,## 59 486.7 ± 51.1&
Saline+ Vehicle – 131.6 ± 42.4 – 711.4 ± 43.2&
Saline+ Capsaicin 4 1.6 ± 0.9** 99 1077.4 ± 52.2**
Saline+ MBI  500 3.0 ± 2.9** 68 991.8 ± 58.1*
RR+ Vehicle – 151.5 ± 12.4 – 647.8 ± 61.8&
RR+ Capsaicin 4 103.8 ± 44.7## 31 967.3 ± 98.3*
RR+ MBI 500 37.7 ± 12.5**,# 75 793.3 ± 34.7&
Data are presented as mean ± S.E.M. ANOVA followed by Dunnett’s test. Ulcerative lesion: *P < 0.05, **P < 0.01 represents difference in relation to control group treated
with  vehicle; #P < 0.05, ##P < 0.001 represents difference in relation to pre-treatments sa
Glutathione & represents difference in relation to untreated group and *P < 0.05, **P < 0
saline  + vehicle, NEM + vehicle or RR + vehicle.
Fig. 2. Gastroprotective activity of methanolic extract of Byrsonima intermedia
(MBI) on level of total glutathione and mieloperoxidase on model of gastric injury
induced by ischemia/ reperfusion in rats (n = 8–10). The bars represent mean ± S.E.M.
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Khe  numbers indicate the percentage protection in relation to the control group
reated with vehicle. ++P < 0.01 for total gluthatione; F(3,21)=9,70 ##P < 0.01 for
yeloperoxidase, ANOVA followed by Dunnett’s test; **P < 0.01.nti-inﬂammatory effect of this species. The phytochemical com-
osition of MBI  (mainly ﬂavonoids) is probably involved in this
esult because a study by Rao and Vijayakumar (2008) has already
escribed the effect of (+)-catechin, the main ﬂavan-3-ol present
ig. 3. Effect of methanolic extract of Byrsonima intermedia (MBI) on level of total glutath
ats  (n = 8–10). The bars represent mean ± S.E.M. The numbers indicate the percentage pr
rusal/Wallis’s test; *P < 0.05, **P < 0.01. ++P < 0.01 for total glutathione; F(3,21) = 9,70 ##p <line + treatment and RR + treatment or saline + treatment and RR + treatment. Total
.01 represents statistical difference in relation to control group pre-treated with
in MBI, as an important gastroprotective compound against gastric
mucosal injury induced by ischemia–reperfusion in rats.
In addition to the protective effect of MBI  in gastric experimen-
tal models in vivo, we also determined the protective effects of MBI
against duodenal lesions induced by cysteamine in rats. Cysteamine
hydrochloride inhibits alkaline mucus secretion from the Brunner’s
gland in the proximal duodenum and stimulates the rate of gas-
tric acid secretion (Schwedes et al., 1977). According to Khomenko
et al. (2009) animals treated with cysteamine also display a sig-
niﬁcant increase in duodenal lesions due to the generation of free
radicals. Fig. 3 shows that duodenal injuries caused by cysteamine
signiﬁcantly decreased upon treatment with MBI  relative to the
group treated with vehicle. The duodenal protective effect of MBI
(69%) was  also accompanied by a signiﬁcant decrease in MPO,  a
marker of neutrophil activity. Neutrophils are the major inﬂam-
matory cell type that inﬁltrates the injured gastroduodenal mucosa.
Our results indicate that MBI  counteracts this inﬁltration to protect
the duodenal mucosa against ulcers.
Based on all of the results regarding the gastroprotective effect of
MBI, the protective effect of this extract against gastric and duode-
nal injuries induced by different ulcerogenic agents was  conﬁrmed.
However, for any new anti-ulcer drug, it is desirable for this pre-
ventive effect to also be accompanied by ulcer-healing effects in
both of these tissues.
ione and mieloperoxidase on model of duodenal injury induced by cysteamine in
otection in relation to the control group treated with vehicle. ANOVA followed by
 0.01 for myeloperoxidase, ANOVA followed by Dunnett’s test; **P < 0.01.
210 R.C. Santos et al. / Journal of Ethnopharmacology 140 (2012) 203– 212
Fig. 4. Gastric healing effect of methanolic extract of Byrsonima intermedia (MBI) by
treatment during 7 or 14 days after injury induced by acetic acid in rats (n = 8).
T
t
D
o
i
p
b
d
t
b
m
t
i
s
b
t
w
i
c
r
d
g
i
a
o
s
F
b
T
t
D
Table 4
Effect of methanolic extract of Byrsonima intermedia (MBI) on intestinal propulsion
induced by activated charcoal in mice.
Treatment (p.o.) Dose (mg/kg) N Distance moved by
charcoal (arcosine)
Vehicle – 7 56.1 ± 2.6
Atropine 5 7 35.8 ± 3.8**
MBI 250 7 62.6 ± 5.0
500 7 51.4 ± 1.9
1000 7 52.4 ± 2.0he  bars represent mean ± S.E.M.. The numbers indicate the percentage protec-
ion in relation to the control group treated with vehicle. ANOVA followed by
unnett’s; *P < 0.05, **P < 0.01.
Okabe and Amagase (2005) have elegantly described the beneﬁt
f the appearance of acetic acid ulcer models for pathophysiolog-
cal and pharmacological studies of peptic ulcers. New drugs that
revent ulcer relapse and enhance ulcer healing could potentially
e developed using this established method. Thus this study also
etermined the effect of MBI  during 7 or 14 consecutive days on
he healing of gastric (Fig. 4) and duodenal ulcers (Fig. 5) induced
y acetic acid in rats.
Due to severity of the lesions induced by acetic acid in the gastric
ucosa of rats, neither lansoprazole nor MBI  were able to heal gas-
ric lesions within 7 consecutive days (Fig. 4). However, the results
n Fig. 4 also show that treatment with MBI  (500 mg/kg) or with lan-
oprazole for 14 consecutive days were able to heal gastric ulcers
y decreasing the lesion area (49% and 59%, respectively) in rela-
ion to the control group treated with vehicle. Fig. 5 shows that MBI
as more effective in healing duodenal ulcers than gastric ulcers
n rats. MBI  was able to heal duodenal ulcers within 7 (44%) and 14
onsecutive days of treatment (45%). Taken together, these results
einforce the marked effect of MBI  in inhibiting gastric and duo-
enal lesions and in promoting the healing of a chronic type of
astric and duodenal ulcer in rats. Other important data obtained
n this assay indicated that during the consecutive treatments of
nimals with MBI  (7 or 14 days), no animals died or showed signs
f toxicity from this extract, such as weight loss. However, more
peciﬁc studies regarding potential in vivo toxicity of MBI  must be
ig. 5. Duodenal healing effect of methanolic extract of Byrsonima intermedia (MBI)
y  treatment during 7 or 14 days after injury induced by acetic acid in rats (n = 8).
he bars represent mean ± S.E.M. The numbers indicate the percentage protec-
ion in relation to the control group treated with vehicle. ANOVA followed by
unnett’s; *P < 0.05, **P < 0.01.Data are presented as mean ± S.E.M. ANOVA followed by Dunnett’s test.
** P < 0.01.
performed, based on data obtained from Sannomiya et al. (2007),
which describes the absence of in vivo mutagenic action of this
extract but the presence of a mutagenic effect in vitro.
Additionally to proving the anti-ulcer activity of MBI, this study
also aimed to evaluate the claimed antidiarrheal effect of the
traditional indication of this species. The relevance of this thera-
peutic effect is demonstrated by intestinal infection being the most
common cause of diarrhea in the world and being responsible for
the deaths of approximately 4 million individuals each year (WHO,
1996).
We started to evaluate this potential effect of MBI  on normal
intestinal propulsion of mice with different doses of the extract
(Table 4). In the MBI-treated group of mice, all doses of extract did
not change the normal intestinal propulsive movement relative to
the atropine group; atropine produced a greater anti-motility effect
(P < 0.05). To evaluate the antidiarrheal effect of MBI, we challenged
this extract against the cathartic agent, castor oil. Oral administra-
tion of castor oil produced a marked and signiﬁcant increase in the
intestinal ﬂuid volume of castor oil-treated mice (Table 5). The stan-
dard drug (morphine) and MBI  (500 mg/kg) produced a signiﬁcantly
inhibitory effect on the castor oil-induced ﬂuid accumulation. These
ﬁnding suggest that this extract produces diarrhea relief through
its anti-enteropooling effect.
We evaluated the antidiarrheal activity of this extract by
pretreament with naloxone (competitive opioid antagonist) to
determine the involvement of opioid receptors at the MBI effects on
management of diarrhea. Our results shown that pretreament with
naloxone was  able to reversed the antidiarrheal effect of MBI  con-
ﬁrming the action MBI  may  occur by opioid receptors. These results
are also in concordance with obtained by Orlandi et al. (2011) that
found expressive antinociceptive activity of Byrsonima intermedia
extract. In this study, the authors suggest that at least part of the
anti-hyperalgesic effect was due to involvement of opioid system.
Table 5
Effects of methanolic extract of Byrsonima intermedia (MBI) on castor oil-induced
enteropooling (ﬂuid accumulation) in mice.
Pretreatment 
(i.p.)
Treatment 
(p.o.)
Dose 
(mg/kg)
Intestinal fluid  N 
(g)
Inhibitio n
(%)
- 1.5 ± 0.1 7 - Vehicle Saline + 
48 0.8 ± 0.1 ** 7 10 Morphine Saline + 
36 0.9 ± 0.1 * 7 500 MBI Saline + 
Naloxone +  Vehicle - 8 1.4 ± 0.1  -
Naloxone + Morphine 10 8 1.4 ± 0.1 ## 0
Naloxone +  MBI 500 8 1.6 ± 0.1 ## -14 
Data are presented as mean ± S.E.M. ANOVA followed by Dunnett’s. *P < 0.05,
**P < 0.01 represents difference in relation to control group treated with vehicle.
##P < 0.01 represents difference in relation to pretreated group with saline and
naloxone.
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Table 6
Preventive and curative effects of methanolic extract of Byrsonima intermedia (MBI) on antidiarrheal induced by castor oil in mice.
Effects Treatment (p.o.) Dose (mg/kg) N Time to initial
evacuation (min)
Evacuation classiﬁcation Evacuation index (EI) Inhibiton (%)a
Normal Semi-solid Liquid
Preventive effect Vehicle – 7 74.1 ± 16.3 1.7 ± 0.3 1.3 ± 0.4 3.9 ± 0.5 15.9 ± 0.9 –
Loperamide 5 7 220.8 ±  19.2** 0.0 ± 0.0** 0.0 ± 0.0 0.5 ± 0.5** 1.5 ± 1.3** 91
MBI  500 7 167.0 ± 30.8* 2.4 ± 0.2 1.6 ± 0.4 0.9 ± 0.6* 8.1 ± 1.9* 49
Curative effect Vehicle – 8 71.1 ± 5.7 1.5 ± 0.3 0.9 ± 0.3 5.0 ± 0.4 18.3 ± 1.2 –
Loperamide 5 9 187.0 ± 28.7** 0.7 ± 0.2 0.6 ± 0.2 0.7 ± 0.2*** 3.8 ± 0.9*** 79
MBI  500 9 103.4 ± 18.8 1.8 ± 0.4 1.1 ± 0.2 2.2 ± 0.4* 10.7 ± 0.7* 42
D *P < 0
b
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pata are presented as mean ± S.E.M. ANOVA followed by Dunnett’s test; *P < 0.05, *
y  Dunn *P < 0.05, **P < 0.01. #Inhibition in relation to evacuation index.
In addition to the preventive effect of MBI  on diarrhea induced
y castor oil, we also evaluated the curative effect of this extract
o reverse existing diarrhea, simulating a more realistic situa-
ion in the therapeutic use of the medicinal plant. The diarrhea
nducing by castor oil is known to be due to ricinoleic acid that
resents a laxative action, cause local irritation, affects intestinal
otility, increases gastrointestinal mucosal permeability, induced
amage of intestinal mucosa and also has pro-inﬂammatory action
y increased prostaglandins levels and activated platelet activat-
ng factors (Izzo et al., 1998; Vieira et al., 2001; Saito et al., 2002).
ll rats in the control group (treated with vehicle) after castor oil
dministration produced copious diarrhea (Table 6). However, pre-
reatment with MBI  (500 mg/kg) induced a signiﬁcant delay in the
nset of the copious diarrhea (49%). The decrease in the sever-
ty of the diarrhea (evacuation index) was almost the same with
re-treatment with MBI  (preventive effect) or post-treatment with
his extract (curative effect). Treatment with MBI  after or before
he cathartic agent (castor oil) was able to produce a signiﬁcant
ecrease in liquid evacuation, similar to loperamide, but only MBI
howed preventive effects by increasing the time to initial evacua-
ion (P < 0.05).
Together, all of these results show that MBI  was able to both
revent and reverse diarrhea induced by the cathartic agent by
ecreasing the liquid faeces and intestinal ﬂuid without changing
he intestinal motility. Our phytochemical study demonstrated the
resence of oligomeric proanthocyanidins in this extract and these
ompounds have been demonstrated antidiarrheal activity (Fischer
t al., 2004). But the presence of compounds such as ﬂavonoids in
BI  with demonstrated anti-inﬂammatory effects also contributes
o antidiarrheal action against the cathartic agent.
The antidiarrheal effects of MBI  were disabled because the
ost common intestinal infections that induce acute watery diar-
hea in approximately 80% of people are caused by Escherichia coli
nd Staphylococcus aureus (Hunter et al., 2010). In this study,
e also evaluated the in vitro antibacterial activity of MBI. MBI
as found to present antibacterial activity against Helicobac-
er pylori (MIC = 0.125 mg/mL). But we also evaluated the effect
f MBI  which the most important pathogenic agents, such as
taphylococcus aureus (MIC = 0.250 mg/mL) and Escherichia coli
MIC = 0.500 mg/mL).
. Conclusions
The present study clearly demonstrates the gastroprotec-
ive, ulcer-healing, antibacterial and antidiarrheal action of the
ethanolic extract from Byrsonima intermedia leaves. The pro-
ective action of the extract against various ulcerogenic agents
s related to the strengthening of the gastric protective barrier
hrough the action of endogenous sulfhydryl compounds, increases
n the glutathione level and activation of vanilloid receptors. The
rotective effect of the extract is also mediated by a reduction of the.01. For classiﬁcation of evacuations and calculation of IE, Kruskal-Wallis followed
myeloperoxidase levels in gastric and duodenal mucosa. The ulcer-
healing action against gastric (14 days) but mostly duodenal ulcers
(7 and 14 days) demonstrated the powerful healing effect of this
extract. This work also conﬁrmed that the anti-diarrheal action of
this extract is executed by decreasing diarrheal faeces and intesti-
nal ﬂuid formation and suggest the involvement of opiate receptors.
These effects of the extract are accompanied by an antimicrobial
action against the most common bacteria that cause ulcers.
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